Introduction: Veterinarians use flumequine (FLU) widely but its toxicological effects are still unclear.
Material and Methods: FLU doses of 53, 200, or 750 mg/kg were administered orally for six weeks to pubertal male rats for evaluation of their toxicity.
Results: Weight gain was poorer after seven days of exposure to FLU 750, but relative weights of the brain, adrenal and thyroid glands, and testes were notably higher. Haematological and lipid profile parameters, cardiac markers, and inorganic phosphate significantly increased in the FLU 750 group. Blood glucose, oestradiol and serum concentrations of immunoglobulins G (IgG) and E (IgE) significantly decreased after treatment. The levels of interleukins 10 (IL-10) and 6 (IL-6) fell significantly in the FLU 200 and FLU 750 groups. Cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) and cyclooxygenase-2 (Cox-2) expression amplified after treatment. Serum levels of free triiodothyronine (fT3) and free thyroxine (fT4) reduced in the FLU 200 and FLU 750 groups without changes in total T3 or T4 level. All doses of FLU significantly depressed concentrations of thyroid-stimulating hormone (TSH) and testosterone. Histopathology of thyroid glands from rats treated with FLU 750 showed degeneration and depletion of thyroid follicular epithelial cells. Expression of 8-hydroxydeoxyguanosine (8-OHdG) was increased in a dose-dependent manner in the brain, but decreased in the testes. Expression of CYP1A1 increased in the adrenal and pituitary glands.
Conclusion: The results of this study suggest that the toxicity of FLU in rats is an effect of its disruptive influence on the pituitary-thyroid hormonal system and on the dysfunction of the immune system.
3. Cheng L., Ming-liang H., Lars B.: Is COX-2 a perpetrator or a protector? Selective COX-2 inhibitors remain controversial. Acta Pharm Sin 2005, 26, 926–933.
4. Cho J.H., Jeong S.H., Ku H.O., Kang H.G., Park J.M., Yun H.I., Lee Y.S.: Improved novel method of blood sample collection via jugular vein in unanaesthetized rats. Korean J Lab Anim Sci 1997, 13, 117–120.
5. Cruz R., Quintana-Hau J.D., Gonzalez J.R., Tornero-Montano R., Baiza-Duran L.M., Vega L.: Effects of an ophthalmic formulation of meloxicam on COX-2 expression, PGE2 release, and cytokine expression in a model of acute ocular inflammation. Br J Ophthalmol 2008, 92, 120–125.
6. Fazili I.S., Jiang W., Wang L., Felix E.A., Khatlani T., Coumoul X., Barouki R., Moorthy B.: Persistent induction of cytochrome P4501A1 in human hepatoma cells by 3-methylcholanthrene: evidence for sustained transcriptional activation of the CYP1A1 promoter. J Pharmacol Exp Ther 2010, 333, 99–109.
7. Geffner J.R., Minnucci F., Isturiz M.A.: Interferon-gamma is unable to increase monocyte and neutrophil-mediated nonspecific cytotoxicity induced by immune complexes. Immunol Lett 1992, 33, 21–25.
8. Groelz D., Sobin L., Branton P., Compton C., Wyrich R., Rainen L.: Non-formalin fixative versus formalin-fixed tissue: A comparison of histology and RNA quality. Exp Mol Pathol 2013, 94, 188–194.
9. Jensen H.S., Mogensen H.H., Kjaersgaard E.: Blood monocyte elastolytic activity enhanced by immune complex stimulation in patients with rheumatoid arthritis and normal controls. Effect of aurothiomalate or D-penicillamine. Scand J Rheumatol 1989, 18, 297–305.
10. Jeong S.H., Kim B.Y., Kang H.G., Ku H.O., Cho J.H.: Effects of butylated hydroxyanisole on the development and functions of reproductive system in rats. Toxicology 2005, 208, 49–62.
11. Joint FAO/WHO Expert Committee on Food Additives (JECFA): Toxicological evaluation of certain veterinary drug residues in food. World Health Organization, Geneva, Switzerland, 2004 WHO Food Additives Series: 51.
12. Kang H.G., Jeong S.H., Cho J.H., Kim D.G., Park J.M., Cho M.H.: Chlropyrifos-methyl shows anti-androgenic activity without estrogenic activity in rats. Toxicology 2004, 199, 219–230.
13. Kuroda K., Kijima A., Ishii Y., Takasu S., Jin M., Matsushita K., Kodama Y., Umemura T.: Flumequine enhances the in vivo mutagenicity of MeIQx in the mouse liver. Arch Toxicol 2013, 87, 1609–1619.
14. Lopez-Giacoman S., Madero M.: Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol 2015, 4, 57–73.
15. OECD/OCDE. OECD guideline for the testing of chemicals. Repeated dose 90-days oral toxicity study in rodents, 1998, p. 408.
16. Rizos C.V., Elisaf M.S., Liberopoulos E.N.: Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J 2011, 5, 76–84.
17. Sanderson J.T.: The Steroid Hormone Biosynthesis Pathway as a Target for Endocrine-Disrupting Chemicals. Toxicol Sci 2006, 94, 3–21.
18. Scharer K.: The effect of chronic underfeeding on organ weights of rats. How to interpret organ weight changes in cases of marked growth retardation in toxicity tests? Toxicology 1977, 7, 45–56.
19. Summary report (2) flumequine (EMEA/MRL/624/99-FINAL), Committee for veterinary medicinal products, the European Agency for the Evaluation of Medicinal Products. 1999.
20. Van der Heijden M.H., Booms G.H., Tanck M.W., Rombout J.H., Boon J.H.: Influence of flumequine on in vivo mitogen responses of European eel (Anguilla anguilla L., 1758) lymphoid cells. Vet Immunol Immunopathol 1995, 47, 143–152.
21. Yoshida M., Miyajima K., Shiraki K., AndoK K.J., Nakae D., Takahashi M., Maekawa A.: Hepatotoxicity and consequently increased cell proliferation are associated with flumequine hepatocarcinogenesis in mice. Cancer Lett 1999, 141, 99–107.